1-20 of 77
trametinib
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Integrative Analysis of FISH, Transcriptomics and Mutational Status Predicts Responsiveness to Novel Agents in Multiple Myeloma

Cecilia Bonolo De Campos, PhD, Caleb K Stein, PhD, Nathalie Meurice, PhD, Laura Ann Bruins, BS, Joachim L Petit, PhD, Alysia N Polito, BS, Gregory J Ahmann, BS, Shulan Tian, MS, PhD, P. Leif Bergsagel, MD, Esteban Braggio, PhD, A. Keith Stewart, MB, ChB
Journal: Blood
Blood (2019) 134 (Supplement_1): 574.
https://doi.org/10.1182/blood-2019-130977
Published: 2019
Journal Articles

Ex Vivo Drug Sensitivity Screens Identify Personalized Treatment Options for CLL Patients

Sigrid Strand Skånland, PhD, Bendiksen Henrik, MSc, Andrea Cremaschi, PhD, Deepak Balaji Thimiri Govinda Raj, PhD, Ludvig Andre Munthe, MD PhD, Geir Erland Tjønnfjord, MD PhD, Kjetil Taskén, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5446.
https://doi.org/10.1182/blood-2019-121890
Published: 2019
Journal Articles

A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera

Jason Gotlib, MD MS, Nashat Gabrail, MD, Casey L. O'Connell, MD, Regina Garcia-Delgado, MD, Timothy Sbardellati, Wayne M. Rothbaum, Jesse McGreivy, Claire N Harrison, Professor, Jean-Jacques Kiladjian, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4168.
https://doi.org/10.1182/blood-2019-123546
Published: 2019
Journal Articles

Population Pharmacokinetic Analysis of the MDM2 Inhibitor KRT-232 (formerly AMG 232) in Subjects with Advanced Solid Tumors, Multiple Myeloma or Acute Myeloid Leukemia

Shu Chin Ma, PhD, Russ Wada, PhD, Martine Allard, PhD, Greg Slatter, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5766.
https://doi.org/10.1182/blood-2019-131331
Published: 2019
Journal Articles

Concentration-QTc (C-QTc) Analysis of the MDM2 Inhibitor KRT-232 (formerly AMG 232) in Subjects with Advanced Solid Tumors, Multiple Myeloma, or Acute Myeloid Leukemia

Adekemi Taylor, PhD, Martine Allard, PhD, Cecile Kresja, PhD, Dana Lee, PharmD, Greg Slatter, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5768.
https://doi.org/10.1182/blood-2019-131481
Published: 2019
Journal Articles

SETBP1 Mutations Accelerate NRAS-Mutant Leukemia

Sarah A Carratt, PhD BS, Zachary Schonrock, BS, Theodore Braun, MD PhD, Cody Coblentz, Amy Foley, MEng., Julia E. Maxson, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1254.
https://doi.org/10.1182/blood-2019-125125
Published: 2019
Journal Articles

MAPK-ERK Pathway Activation: The Achilles' Heel of IL-7R‒Induced Steroid Resistance

Jordy C.G. Van Der Zwet, MD, Jessica G.C.A.M. Buijs-Gladdines, Willem K. Smits, Zhongli Chen, MSc, Jules P.P. Meijerink, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1292.
https://doi.org/10.1182/blood-2019-124721
Published: 2019
Journal Articles

A Multi-Omic Precision Medicine Clinical Trial in Acute Leukemia

Pamela S. Becker, MD PhD, Vivian G. Oehler, MD, Carl Anthony Blau, MD, Timothy S Martins, PhD, Niall Curley, Sylvia Chien, Jin Dai, PhD, Nicole Kauer, Ka Yee Yeung, PhD, Ling-Hong Hung, PhD, Cody Hammer, Paul C. Hendrie, MD PhD, Mary-Elizabeth M. Percival, MD, Ryan D. Cassaday, MD, Bart L. Scott, MD, Roland B. Walter, MD PhD MS, Kelda Gardner, PA-C, Mary Gwin, Heather Smith, PA-C, Andrew Carson, PhD, Bradley Patay, MD, Elihu H. Estey, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1269.
https://doi.org/10.1182/blood-2019-130996
Published: 2019
Journal Articles

Molecular Alterations in Adult Histiocytic Neoplasms

Gaurav Goyal, MBBS, Jithma P. Abeykoon, MD, Nora N Bennani, MD, Minetta C Liu, MD, Mithun Vinod Shah, MD PhD, Ronald S. Go, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2975.
https://doi.org/10.1182/blood-2019-122286
Published: 2019
Journal Articles

An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor

Regina Garcia-Delgado, MD, Donal P. McLornan, MB, BCh (Hons), MRCP, PhD FRCPath, László Rejtő, Eric Jourdan, MD, Haifa Kathrin Al-Ali, MD, Andrzej Pluta, MD, Marek Hus, MD PhD, Joanne Ewing, PhDBMBS BSc FRPATH, Irum Khan, MD, Holger Hebart, Philipp J. Jost, MD, Sebastian Grosicki, MD PhD, Wayne M. Rothbaum, Jesse McGreivy, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2945.
https://doi.org/10.1182/blood-2019-123836
Published: 2019
Journal Articles

Loss of Asxl1 Cooperates with Oncogenic Nras to Drive CMML Progression

Xiaona You, PhD, Zhi Wen, PhD, Guangyao Kong, Adhithi Rajagopalan, BS, Erik A. Ranheim, MD PhD, Yun Zhou, MS, Mrinal M Patnaik, MDMBBS, Jing Zhang, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3790.
https://doi.org/10.1182/blood-2019-131347
Published: 2019
Journal Articles

MEK Inhibition with Trametinib in Patients with Non-Langerhans Cell Histiocytosis

Filip Janku, MD PhD, Harsh Patel, BS, Vaijayanthi Kandadai Raghavan, Aaron Goodman, Tamara G. Barnes, Razelle Kurzrock, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2319.
https://doi.org/10.1182/blood-2019-126342
Published: 2019
Journal Articles

Combination of the MEK Inhibitor Trametinib and Pyrvinium Pamoate Efficiently Targets RAS Pathway-Mutated Acute Myeloid Leukemia in Preclinical Models

Justine Decroocq, MD, Rudy Birsen, MD, Jordi Mano, MSc, Guillemette Fouquet, Mathilde Gotanègre, MSc, Laury Poulain, PhD, Sarah Mouche, Anne-Sophie Alary, Adrien Grenier, MD PhD, Fetta Mazed, PhD, Johanna Mondesir, MD, Nicolas Chapuis, PharmD, PhD, Aicha Boughalem, MD, Marc Le Lorc'h, Ivan C Moura, PhD, Olivier Hermine, MD PhD, Isabelle Radford-Weiss, Jean-Emmanuel Sarry, PhD, Eric Pasmant, MD PhD, Olivier Kosmider, PharmD, PhD, Didier Bouscary, MD PhD, Jerome Tamburini, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2671.
https://doi.org/10.1182/blood-2019-123418
Published: 2019
Journal Articles

Patterns of Sensitivity Exhibited By Venetoclax-Inclusive Drug Combinations in Acute Myeloid Leukemia

Stephen E Kurtz, PhD, Christopher A. Eide, Andy Kaempf, MS, Nicola Long, Anupriya Agarwal, PhD, Cristina E. Tognon, Motomi Mori, PhD, Brian J. Druker, Jeffrey W. Tyner
Journal: Blood
Blood (2019) 134 (Supplement_1): 878.
https://doi.org/10.1182/blood-2019-126020
Published: 2019
Journal Articles

The MEK Inhibitor Trametinib Enhances Diverse T Cell Reconstitution with Suppressing Xenogeneic Graft-Versus-Host-Disease

Hidekazu Itamura, MD PhD, Hiroyuki Muranushi, MD, Takero Shindo, MD PhD, Kazutaka Kitaura, DVM, PhD, Seiji Okada, MD PhD, Tadasu Shin-I, PhD, Ryuji Suzuki, DVM, PhD, Akifumi Takaori-Kondo, MD PhD, Shinya Kimura, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1929.
https://doi.org/10.1182/blood-2019-128913
Published: 2019
Journal Articles

Genome-Wide CRISPR Screening in Acute Myeloid Leukemia Cells Identifies Genes in the PI3K/AKT/mTOR and MEK/ERK Pathways That Define Sensitivity to Trametinib

Tamilla Nechiporuk, PhD, Alisa Damnernsawad, PhD, Daniel Bottomly, MS, Quinlan Morrow, BS, Suyoun Choi, Sofia Beer, Stephen E Kurtz, PhD, Shannon K. McWeeney, PhD, Jeffrey W. Tyner
Journal: Blood
Blood (2019) 134 (Supplement_1): 1395.
https://doi.org/10.1182/blood-2019-129117
Published: 2019
Journal Articles

Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLL

Shanye Yin, PhD, Salma Parvin, PhD, Elisa Ten Hacken, PhD, Rebecca Valentin, MD, Heather Joyal, Laura Z. Rassenti, PhD, Emanuela M. Ghia, PhD, Thomas J. Kipps, MD PhD, Donna S Neuberg, ScD, Lili Wang, MD PhD, Matthew S. Davids, MD, Ruben D. Carrasco, MD PhD, Anthony G. Letai, MD PhD, Catherine J. Wu, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4281.
https://doi.org/10.1182/blood-2019-127293
Published: 2019
Journal Articles

Investigation of New Therapeutic Compounds for Juvenile Myelomonocytic Leukemia Using Induced Pluripotent Stem Cells with Stably Activated Ras Pathway

Lisa Maria Kuhn, Cyrill Schipp, PhD, Daniel Hein, PhD, Bianca Killing, Nan Qin, PhD, Vera H Jepsen, M.Sc., Heinz Ahlert, MSc, BSc, Jasmin Bartl, PhD, Viktoria Marquardt, M.Sc., David Pauck, Kai Völtzke, M.Sc., Jonathan Lim, PhD, Gabriel Leprivier, PhD, Marc Remke, MD, Sanil Bhatia, PhD, Thorsten Rosenbaum, MD, Arndt Borkhardt, MD, Ute Fischer, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4651.
https://doi.org/10.1182/blood-2019-131406
Published: 2019
Journal Articles

Next Generation Sequencing May be Helpful in Designing Novel Combinations Among Heavily Pretreated Myeloma Patients, Refractory to All Available Approved Anti-Myeloma Drugs

Guldane Cengiz Seval, Isinsu Kuzu, Seher Yuksel, Gulsah Kaygusuz, Klara Dalva, MD, Muhit Ozcan, Meral Beksac, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3197.
https://doi.org/10.1182/blood-2019-127541
Published: 2019
Journal Articles

Characterizing Population Heterogeneity and Signaling Changes in Chronic Myeloid Leukemia Stem and Progenitor Cells upon Combined Treatment with Imatinib and MEK Inhibitors Using Quantitative Single Cell Phospho-Imaging

Anna Reister Schultz, BS, Thomas Jacob, Christopher A. Eide, Samantha L Savage, Motomi Mori, PhD, Jeffrey W. Tyner, PhD, Cristina E. Tognon, PhD, Tania Q. Vu, Brian J. Druker, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4248.
https://doi.org/10.1182/blood-2018-99-115387
Published: 2018